Expediting in Vitro Characterization of mRNA-Based Gene Therapies via High-Content Fluorescent Imaging


Authors: T.N. Vigila, D. Zhang-Hulsey, J.L. Santos and G.P. Hussmann

Journal: Analytical Biochemistry

DOI: https://doi.org/10.1016/j.ab.2021.114259

Publication - Abstract

August 15, 2021

A study conducted by Vigil et al. 2021 from Astrazeneca Biopharmaceuticals R&D showcases the applicability of high-content fluorescent imaging as a technique for the rapid characterization of mRNA-LNPs generated from a NanoAssemblr® mixing device in order to determine the optimal conditions for transfection that minimize cellular cytotoxicity and maximize mRNA internalization. Through high-content fluorescent imaging, mRNA-LNP characteristics such as transfection parameters, transfection-induced cytotoxicity, mRNA delivery, and mRNA translation were investigated in HEPG2 two dimensional monolayer and three dimensional spheroid cell cultures. This research demonstrates the value in utilizing high fluorescent imaging especially for future studies toward the development of novel gene therapies and drug candidates for various disease areas.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Delivery of therapeutic nucleic acids in general and small interfering RNAs (siRNAs) in particular although a relatively nascent area of research, has already overcome several technical and regulatory hurdles over past few years.

Read More


Publication - Abstract

The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR).
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.